<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2015">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640233</url>
  </required_header>
  <id_info>
    <org_study_id>RDI-GCV-001</org_study_id>
    <secondary_id>CTRI/2020/11/029234</secondary_id>
    <nct_id>NCT04640233</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RDIF (Russian Direct Investment Fund)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CRO: JSS Medical Research India Pvt. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III&#xD;
      Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined&#xD;
      Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III&#xD;
      Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined&#xD;
      Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects.&#xD;
&#xD;
      In phase II trial, 100 subjects of immunogenicity group will be enrolled in 3:1&#xD;
      (Test:Placebo) ratio. These 100 subjects will be assessed for safety and immunogenicity&#xD;
      outcomes till Day 28 post the first dose of investigational medicinal product (IMP)/placebo&#xD;
      administration and will continue with study assessments till Day 180. Safety and&#xD;
      immunogenicity data collected till Day 28 will be submitted to the regulatory authority for&#xD;
      recommendation to proceed with Phase III recruitment.&#xD;
&#xD;
      In Phase III trial, 1500 subjects will be enrolled and randomized in the ratio of 3:1&#xD;
      (Gam-COVID--Vac : Placebo).&#xD;
&#xD;
      Each subject will participate in this adaptive study phase II/III clinical trial for 180±14&#xD;
      days after the first dose of the IMP/placebo and will have one screening visit and seven&#xD;
      on-site visits during the trial period. The IMP/placebo will be administered intramuscularly&#xD;
      during vaccination Visits 1 and 3 (Day 1 and Day 21±2). The observation Visits 2, 4, 5, 6,&#xD;
      and 7 will be made on Day 19±2, Day 28±2, Day 42±2, Day 90±7, and Day 180±14, respectively.&#xD;
      During the observation visits, vital indicators will be assessed in all subjects and changes&#xD;
      in the subjects' condition and well being compared to the previous visit will be recorded.&#xD;
      The schedule of examination procedures is mentioned in the Schedule of Event tables.&#xD;
&#xD;
      Additionally, the subjects will be able to have remote consultations with the study physician&#xD;
      through the weekly telephonic follow-up.&#xD;
&#xD;
      Blood samples will be taken from immunogenicity group of phase II (all 100) and phase III&#xD;
      (284 out of 1500) trials during the following visits to assess the immunogenicity parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>For Phase II study - at Day 28; For Phase III study - till day 180 after first dose</time_frame>
    <description>For Phase II study - - Incidence &amp; severity of adverse events (AEs) after first dose of IMP/Placebo&#xD;
For Phase III study -&#xD;
- Incidence of related serious adverse events (SAEs) following vaccination during the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>For Phase II study - Day 28 after first dose</time_frame>
    <description>For Phase II study -&#xD;
- Seroconversion rate of SARS-CoV-2 glycoprotein-specific antibodies in immunogenicity group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>For Phase III study - Day 42 after first dose</time_frame>
    <description>For Phase III study - Geometric mean titre ratio of SARS-CoV-2 glycoprotein-specific antibodies between IMP and placebo in immunogenicity group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline to Day 180</time_frame>
    <description>Incidence and severity of adverse events after injecting the first dose of the IMP/placebo&#xD;
Incidence of SAE following vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment</measure>
    <time_frame>Baseline, Day 21, Day 28, Day 42, Day 90, and Day 180</time_frame>
    <description>Seroconversion rate of SARS-CoV-2 glycoprotein-specific antibodies in immunogenicity group&#xD;
Seroconversion rate of SARS-CoV-2 virus-neutralizing antibodies in immunogenicity group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment</measure>
    <time_frame>Baseline, Day 21, Day 28, Day 42, Day 90, and Day 180</time_frame>
    <description>Geometric mean virus-neutralizing antibodies titre in immunogenicity group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment</measure>
    <time_frame>Baseline, Day 28, Day 42, Day 90 and Day 180</time_frame>
    <description>Interferon gamma concentration in T-cells after restimulation with the SARS-CoV-2 glycoprotein in cell mediated immunogenicity group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment</measure>
    <time_frame>Baseline, Day 28, Day 42, Day 90 and Day 180</time_frame>
    <description>The number of proliferating cluster of differentiation 4 (CD4) cell and cluster of differentiation 8 (CD8) cells in response to mitogen stimulation in cell mediated immunogenicity group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with mild, moderate, severe coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose of the vaccine/placebo</measure>
    <time_frame>Baseline to Day 180</time_frame>
    <description>Comparing percentage of subjects developing COVID-19 disease between Gam-COVID-Vac combined vector vaccine and placebo based on severity course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose in trial subjects</measure>
    <time_frame>Baseline to Day 180</time_frame>
    <description>Comparing incidence of COVID-19 disease between Gam-COVID-Vac combined vector vaccine and placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>COVID-19 Prevention</condition>
  <arm_group>
    <arm_group_label>Primary Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gam-COVID-Vac combined vector vaccine, 0.5 ml/dose + 0.5 ml/dose prime-boost immunization on day 1 (component I rAd26-S) and on day 21 (component II rAd5-S)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 0.5 ml/dose + 0.5 ml/dose immunization on days 1 and 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gam-COVID-Vac</intervention_name>
    <description>Vaccine for intramuscular injection</description>
    <arm_group_label>Primary Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent of a subject to participate in the trial&#xD;
&#xD;
          2. Males and females aged 18+ years&#xD;
&#xD;
          3. Negative human immunodeficiency virus (HIV 1 &amp; 2) and hepatitis B and C test results&#xD;
&#xD;
          4. Negative immunoglobulin M (IgM) and immunoglobulin G (IgG) SARS-CoV-2 antibodies&#xD;
             through enzyme immunoassay test result&#xD;
&#xD;
          5. Negative COVID-2019 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) test&#xD;
             result at the screening visit (72 hours prior to Visit 1 [Day 1])&#xD;
&#xD;
          6. No COVID-2019 in the medical history&#xD;
&#xD;
          7. History of no contact with COVID-2019 persons within at least 14 days before the&#xD;
             enrolment (according to subjects)&#xD;
&#xD;
          8. Consent for using effective methods of contraception during the entire trial 1&#xD;
&#xD;
          9. Negative urine pregnancy test at the screening visit (for child-bearing age women)&#xD;
&#xD;
         10. No evident vaccine-induced reactions or complications after receiving immunobiological&#xD;
             products in the medical history&#xD;
&#xD;
         11. No acute infectious and/or respiratory diseases within at least 14 days before the&#xD;
             enrolment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any vaccination/immunization within 30 days before the enrolment&#xD;
&#xD;
          2. Steroids (except hormonal contraceptives) and immunoglobulins or other blood products&#xD;
             therapy not finished 30 days before the enrolment&#xD;
&#xD;
          3. Immunosuppressors therapy finished within 3 months before the enrolment&#xD;
&#xD;
          4. Pregnancy or breast-feeding&#xD;
&#xD;
          5. Acute coronary syndrome or stroke suffered less than one year before the enrolment&#xD;
&#xD;
          6. Tuberculosis, chronic systemic infections&#xD;
&#xD;
          7. Drug allergy (anaphylactic shock, Quincke edema, polymorphic exudative eczema, atopy,&#xD;
             serum disease),hypersensitivity or allergic reaction to immunobiological products,&#xD;
             known allergic reactions to study product components, acute exacerbation of allergic&#xD;
             diseases on the enrolment day&#xD;
&#xD;
          8. Subjects who are on drugs that could have potential drug interactions with adenovirus&#xD;
             vaccine&#xD;
&#xD;
          9. Medical history of malignancy&#xD;
&#xD;
         10. Donated blood or plasma (450+ mL) within 2 months before the enrolment&#xD;
&#xD;
         11. Splenectomy in the medical history&#xD;
&#xD;
         12. Neutropenia (absolute neutrophil count less than 1,000 mm3), agranulocytosis,&#xD;
             significant blood loss,severe anaemia (haemoglobin less than 80 g/L), immunodeficiency&#xD;
             including autoimmune disorders in the medical history within 6 months before the&#xD;
             enrolment&#xD;
&#xD;
         13. Active form of a disease caused by the HIV and hepatitis B or C&#xD;
&#xD;
         14. Anorexia, protein deficiency of any origin&#xD;
&#xD;
         15. Tattoos at the injection site (deltoid muscle area), which does not allow assessing&#xD;
             the local response to the IMP or placebo administration&#xD;
&#xD;
         16. Alcohol or drug addiction in the medical history.&#xD;
&#xD;
         17. Participation in any other interventional clinical trial within 1 month prior to the&#xD;
             Screening&#xD;
&#xD;
         18. Any other medical condition that would limit the participation of the subject as per&#xD;
             Investigator discretion&#xD;
&#xD;
         19. Study centre staff or other employees directly involved in the trial and their&#xD;
             families&#xD;
&#xD;
         20. Subjects contraindicated for vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Lalit Lakhwani, MD</last_name>
    <phone>7337341886</phone>
    <email>lalitkl@drreddys.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr. Agam Shah, MD</last_name>
    <phone>9825465938</phone>
    <email>agam.shah@drreddys.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S N Medical College</name>
      <address>
        <city>Agra</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prabhat Kumar Agarwal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MGM Medical College and Hospital</name>
      <address>
        <city>Aurangabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Nikalje</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KLE Prabhakar Kore Hospital</name>
      <address>
        <city>Belgaum</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayaprakash Appajigol</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viny Kantroo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Batra Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SuninderSingh Arora</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIMSR with CHRD-SAS</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Kohli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ESIC Medical College &amp; Hospital</name>
      <address>
        <city>Faridabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asim Das, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AIG hospital</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P Naveen Reddy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maharaja Agrasen Superspecialty Hospital</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish K Jain, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GSVM Medical College</name>
      <address>
        <city>Kanpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saurabh Agarwal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peerless Hospital</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subhrojyoti Bhowmick</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atharva Hospital</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Gupta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akash Khobragade, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSS Hospital</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shilpa Avarebeel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>INCLEN trust and Gurunanak Hospital</name>
      <address>
        <city>Palwal</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhishek Agarwal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PIMS</name>
      <address>
        <city>Puducherry</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Purty</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BJ Sassoon Hospital</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rohidas Tanku</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KEM Hospital</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Kawade</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Noble Hospital Private Limited</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S K Raut, MBBS, DIH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BAPS hospital</name>
      <address>
        <city>Sūrat</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parshottam Koradia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rhythm Heart Institute</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirav Bhalani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sumandeep Vidyapeeth</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arti Shah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winsley Rose</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sputnik</keyword>
  <keyword>Gamaleya</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

